Hossein Borghaei
Fox Chase Cancer Center · 30 works · 9,423 citations · h-index 7
Top works
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- OA10.03 Tarlatamab Sustained Clinical Benefit and Safety in Previously Treated SCLC: DeLLphi-301 Phase 2 Extended Follow-up
- OA14.03 Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227
- EP14.01-015 IMforte: A Phase III Study of Lurbinectedin and Atezolizumab Versus Atezolizumab as Maintenance Therapy in ES-SCLC
- OA12.05 Phase 1 Updated Exploration and First Expansion Data for DLL3-targeted T-cell Engager Tarlatamab in Small Cell Lung Cancer
- PL03.06 EA5181: Phase 3 Trial of Concurrent and Consolidative Durvalumab vs Consolidation Durva Alone for Unresectable Stage 3 NSCLC
- 281P Development and validation of a living decision support tool (Living-DST) in non-small cell lung cancer (NSCLC) using agentic AI-augmented systematic literature review (SLR)
- KEYNOTE-867: Phase 3, Randomized, Placebo-Controlled Study of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab in Patients with Unresected Stage I or II Non–Small-Cell Lung Cancer (NSCLC)
- 195MO Tarlatamab in previously treated small cell lung cancer (SCLC): DeLLphi-300 phase I study long-term outcomes and intracranial activity
- 384P Prevalence of fibroblast growth factor receptor 2b (FGFR2b) protein overexpression in squamous non-small cell lung cancer (sqNSCLC)
- P4.11D.01 TRITON: Tremelimumab + Durvalumab + Chemotherapy (CT) vs Pembrolizumab + CT in mNSCLC with STK11, KEAP1 and/or KRAS Mutations
- 147P Characterizing CRS in phase I study of DLL3-targeted T cell engager tarlatamab in small cell lung cancer
- 75TiP A multicenter, open-label, phase II trial evaluating the safety and efficacy of folate receptor alpha (FRα) antibody-drug conjugate (ADC) farletuzumab ecteribulin (FZEC*) in patients with previously treated, metastatic non-small cell lung cancer (NSCLC) adenocarcinoma (AC)
- 245P Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Exploratory results of biomarker, updated efficacy and safety analyses from the phase III IMforte trial
- EP16.03-021 Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)
- Synergistic Expression of the Abscopal Effect in a Murine Tumor Model Treated with Combined Radiation and Single or Dual-Immune Checkpoint Blockade
- OA01.01 Pembrolizumab Plus Chemotherapy for Advanced NSCLC without Tumor PD-L1 Expression: Pooled Analysis of KN021G, KN189 and KN407
- Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung)
- 423P IMforte: Subsequent treatment (Tx) following first-line maintenance (1Lm) with lurbinectedin (lurbi) + atezolizumab (atezo) or atezo in extensive stage small cell lung cancer (ES-SCLC)
- 41P Efficacy of first-line (1L) nivolumab (N) + ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC)